Investors sold off shares after Novo’s disappointing Cagrisema readout in December, but the company believes more trial results will show it can be the future of obesity treatment.
Novo Nordisk has just reported better-than-expected full-year results, with both revenues and profits lifted by 25% thanks to rocketing sales of its semaglutide GLP-1 agonist blockbusters, Ozempic for diabetes and Wegovy for obesity.
That saw total global sales rise to DKK290.4bn ($40.6bn), with Ozempic sales rising by 26% to around $16
The total US obesity market grew an astonishing 160% last year, with Novo controlling 63% of the GLP-1 market across diabetes and
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
